Goldman Sachs predicts weight-loss drugs to boost US GDP

Goldman Sachs predicts that the use of weight-loss drugs in the US could increase GDP by 1%. The market for these drugs may reach $100bn annually by 2030. GLP-1 agonists, pursued by companies like Novo Nordisk and Eli Lilly, could see 10-70 million users by 2028. The drugs could boost US GDP by 0.4-1%. Healthcare innovation, including AI and GLP-1s, could raise GDP by 1.3%. Weight-loss drugs are also being researched for other conditions.